Synonyms: HOE-901 | HOE901 | Lantus®
insulin glargine is an approved drug (FDA and EMA (2000))
Compound class:
Peptide
Comment: Insulin glargine is a recombinant, modified analogue of human insulin. The chemical structure shown here was generated using the SMILES from PubChem CID 44146714.
A number of insulin glargine biosimilars have been approved internationally since the expiration of patents on Lantus® in 2014: a comprehensive list that is maintained by the Generics and Biosimilar Initiative (https://www.gabionline.net) is available here. The first fully interchangeable biosimilar to be FDA approved was Semglee® (insulin glargine-yfgn; Mylan Pharmaceuticals), in July 2021. View more information in the IUPHAR Pharmacology Education Project: glargine |
|
Classification | |
Compound class | Peptide |
Approved drug? | Yes (FDA and EMA (2000)) |
International Nonproprietary Names | |
INN number | INN |
7548 | insulin glargine |
Synonyms |
HOE-901 | HOE901 | Lantus® |
Database Links | |
CAS Registry No. | 160337-95-1 |
ChEMBL Ligand | CHEMBL1201497 |
DrugBank Ligand | DB00047 |
GtoPdb PubChem SID | 223365908 |
PubChem CID | 44146714 |
Search Google for chemical match using the InChIKey | COCFEDIXXNGUNL-RFKWWTKHSA-N |
Search Google for chemicals with the same backbone | COCFEDIXXNGUNL |
Search PubMed clinical trials | insulin glargine |
Search PubMed titles | insulin glargine |
Search PubMed titles/abstracts | insulin glargine |
UniChem Compound Search for chemical match using the InChIKey | COCFEDIXXNGUNL-RFKWWTKHSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | COCFEDIXXNGUNL-RFKWWTKHSA-N |
Wikipedia | Insulin glargine |